PULM

Pulmatrix, Inc.

News

gurufocus.comPulmatrix Announces First Quarter 2026 Financial Resultsgurufocus.comMay 15

prnewswire.comPulmatrix Announces First Quarter 2026 Financial Resultsprnewswire.comMay 15

prnewswire.comPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Mergerprnewswire.comApr 21

businesswire.comPULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.comApr 13

defenseworld.netPulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?defenseworld.netApr 11

Trade PULM

About Pulmatrix, Inc.

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

CEO: Peter Ludlum
IPO Date: Mar 21, 2014

Market Data

Open: $1.48
High: $1.51
Low: $1.41
Volume: 1.2M
Avg Volume: 63.9K
52W High: $9.15
52W Low: $1.16

Valuation

Market Cap: $5.3M
Enterprise Value: $2.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-5.4M
Revenue: $0
Net Income: $-5.2M
Cash: $4.1M
Debt: $0

Events

EarningsAug 12